Riociguat Clinical Trials for Pulmonary Hypertension

Wendy Henderson avatar

by Wendy Henderson |

Share this article:

Share article via email


In this webcast shared by the American College of Cardiology, we find out more about the use of riociguat for the treatment of pulmonary hypertension (PH).  

Two-year study of riociguat as CTEPH treatment identifies predictive disease markers. Find out more.

Dr. Chris Cannon discusses two studies, CHEST-1 and PATENT-1, of pulmonary hypertension patients and found that those who were taking riociguat showed significant improvement over those taking a placebo. The first study, PATENT-1, covered 443 patients and showed improvement in the six-minute walk test by an average of 36 meters and an improvement in pulmonary vascular resistance. The second clinical trial, CHEST-1, covered 261 patients and saw a 46-meter improvement in the six-minute walk test and similar improvement in pulmonary vascular resistance.

Riociguat’s broad positive impact includes PAH associated with connective tissue disease. Find out more.

Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.